Does the media refer more to CTMX or SRPT?

In the previous week, Sarepta Therapeutics had 4 more articles in the media than CytomX Therapeutics. MarketBeat recorded 15 mentions for Sarepta Therapeutics and 11 mentions for CytomX Therapeutics. CytomX Therapeutics' average media sentiment score of 1.08 beat Sarepta Therapeutics' score of 0.76 indicating that CytomX Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CytomX Therapeutics 8 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Sarepta Therapeutics 8 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor EDIT or SRPT?

In the previous week, Sarepta Therapeutics had 12 more articles in the media than Editas Medicine. MarketBeat recorded 15 mentions for Sarepta Therapeutics and 3 mentions for Editas Medicine. Editas Medicine's average media sentiment score of 0.92 beat Sarepta Therapeutics' score of 0.76 indicating that Editas Medicine is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Editas Medicine 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Sarepta Therapeutics 8 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to PTCT or SRPT?

In the previous week, PTC Therapeutics had 6 more articles in the media than Sarepta Therapeutics. MarketBeat recorded 21 mentions for PTC Therapeutics and 15 mentions for Sarepta Therapeutics. PTC Therapeutics' average media sentiment score of 0.91 beat Sarepta Therapeutics' score of 0.76 indicating that PTC Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PTC Therapeutics 13 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Sarepta Therapeutics 8 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor XENE or SRPT?

In the previous week, Xenon Pharmaceuticals had 6 more articles in the media than Sarepta Therapeutics. MarketBeat recorded 21 mentions for Xenon Pharmaceuticals and 15 mentions for Sarepta Therapeutics. Xenon Pharmaceuticals' average media sentiment score of 1.40 beat Sarepta Therapeutics' score of 0.76 indicating that Xenon Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Xenon Pharmaceuticals 16 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Sarepta Therapeutics 8 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Sarepta Therapeutics (SRPT) Competitors

$14.86 -0.70 (-4.50%)

Closing price 07/31/2026 04:00 PM Eastern

Extended Trading

$14.88 +0.02 (+0.10%)

As of 07/31/2026 07:59 PM Eastern

Compare

SRPT vs. CTMX, EDIT, PTCT, XENE, and CNTA

Should you buy Sarepta Therapeutics stock or one of its competitors? MarketBeat compares Sarepta Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Sarepta Therapeutics include CytomX Therapeutics (CTMX), Editas Medicine (EDIT), PTC Therapeutics (PTCT), Xenon Pharmaceuticals (XENE), and Centessa Pharmaceuticals (CNTA).

How does Sarepta Therapeutics compare to CytomX Therapeutics?

CytomX Therapeutics (NASDAQ:CTMX) and Sarepta Therapeutics (NASDAQ:SRPT) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, valuation, dividends, profitability, risk, analyst recommendations, institutional ownership and media sentiment.

In the previous week, Sarepta Therapeutics had 4 more articles in the media than CytomX Therapeutics. MarketBeat recorded 15 mentions for Sarepta Therapeutics and 11 mentions for CytomX Therapeutics. CytomX Therapeutics' average media sentiment score of 1.08 beat Sarepta Therapeutics' score of 0.76 indicating that CytomX Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CytomX Therapeutics	8 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Sarepta Therapeutics	8 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

CytomX Therapeutics has higher earnings, but lower revenue than Sarepta Therapeutics. Sarepta Therapeutics is trading at a lower price-to-earnings ratio than CytomX Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CytomX Therapeutics	$76.20M	6.92	-$17.37M	-$0.41	N/A
Sarepta Therapeutics	$2.20B	0.71	-$713.41M	-$0.96	N/A

67.8% of CytomX Therapeutics shares are owned by institutional investors. Comparatively, 86.7% of Sarepta Therapeutics shares are owned by institutional investors. 3.8% of CytomX Therapeutics shares are owned by company insiders. Comparatively, 6.9% of Sarepta Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Sarepta Therapeutics has a net margin of -2.94% compared to CytomX Therapeutics' net margin of -166.40%. Sarepta Therapeutics' return on equity of 7.56% beat CytomX Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CytomX Therapeutics	-166.40%	-36.61%	-28.02%
Sarepta Therapeutics	-2.94%	7.56%	2.94%

CytomX Therapeutics has a beta of 2.12, meaning that its stock price is 112% more volatile than the broader market. Comparatively, Sarepta Therapeutics has a beta of 0.24, meaning that its stock price is 76% less volatile than the broader market.

CytomX Therapeutics currently has a consensus price target of $12.10, indicating a potential upside of 290.32%. Sarepta Therapeutics has a consensus price target of $24.72, indicating a potential upside of 66.37%. Given CytomX Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe CytomX Therapeutics is more favorable than Sarepta Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CytomX Therapeutics	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	3.00
Sarepta Therapeutics	6 Sell rating(s)	6 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.14

Summary

CytomX Therapeutics beats Sarepta Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Sarepta Therapeutics compare to Editas Medicine?

Editas Medicine (NASDAQ:EDIT) and Sarepta Therapeutics (NASDAQ:SRPT) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their media sentiment, earnings, dividends, valuation, institutional ownership, profitability, risk and analyst recommendations.

Editas Medicine has higher earnings, but lower revenue than Sarepta Therapeutics. Sarepta Therapeutics is trading at a lower price-to-earnings ratio than Editas Medicine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Editas Medicine	$40.52M	6.23	-$160.06M	-$1.23	N/A
Sarepta Therapeutics	$2.20B	0.71	-$713.41M	-$0.96	N/A

Editas Medicine has a beta of 2.14, suggesting that its share price is 114% more volatile than the broader market. Comparatively, Sarepta Therapeutics has a beta of 0.24, suggesting that its share price is 76% less volatile than the broader market.

Editas Medicine presently has a consensus target price of $5.40, suggesting a potential upside of 109.30%. Sarepta Therapeutics has a consensus target price of $24.72, suggesting a potential upside of 66.37%. Given Editas Medicine's stronger consensus rating and higher probable upside, equities research analysts clearly believe Editas Medicine is more favorable than Sarepta Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Editas Medicine	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Sarepta Therapeutics	6 Sell rating(s)	6 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.14

Sarepta Therapeutics has a net margin of -2.94% compared to Editas Medicine's net margin of -281.59%. Sarepta Therapeutics' return on equity of 7.56% beat Editas Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Editas Medicine	-281.59%	-677.39%	-58.25%
Sarepta Therapeutics	-2.94%	7.56%	2.94%

In the previous week, Sarepta Therapeutics had 12 more articles in the media than Editas Medicine. MarketBeat recorded 15 mentions for Sarepta Therapeutics and 3 mentions for Editas Medicine. Editas Medicine's average media sentiment score of 0.92 beat Sarepta Therapeutics' score of 0.76 indicating that Editas Medicine is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Editas Medicine	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Sarepta Therapeutics	8 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

71.9% of Editas Medicine shares are owned by institutional investors. Comparatively, 86.7% of Sarepta Therapeutics shares are owned by institutional investors. 3.1% of Editas Medicine shares are owned by insiders. Comparatively, 6.9% of Sarepta Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Sarepta Therapeutics beats Editas Medicine on 9 of the 16 factors compared between the two stocks.

How does Sarepta Therapeutics compare to PTC Therapeutics?

PTC Therapeutics (NASDAQ:PTCT) and Sarepta Therapeutics (NASDAQ:SRPT) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, media sentiment, dividends, risk, valuation, profitability and institutional ownership.

Sarepta Therapeutics has a net margin of -2.94% compared to PTC Therapeutics' net margin of -3.80%. Sarepta Therapeutics' return on equity of 7.56% beat PTC Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PTC Therapeutics	-3.80%	-362.45%	-1.32%
Sarepta Therapeutics	-2.94%	7.56%	2.94%

In the previous week, PTC Therapeutics had 6 more articles in the media than Sarepta Therapeutics. MarketBeat recorded 21 mentions for PTC Therapeutics and 15 mentions for Sarepta Therapeutics. PTC Therapeutics' average media sentiment score of 0.91 beat Sarepta Therapeutics' score of 0.76 indicating that PTC Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
PTC Therapeutics	13 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Sarepta Therapeutics	8 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

86.7% of Sarepta Therapeutics shares are held by institutional investors. 5.3% of PTC Therapeutics shares are held by company insiders. Comparatively, 6.9% of Sarepta Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

PTC Therapeutics has higher earnings, but lower revenue than Sarepta Therapeutics. PTC Therapeutics is trading at a lower price-to-earnings ratio than Sarepta Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PTC Therapeutics	$1.73B	3.26	$682.64M	-$0.58	N/A
Sarepta Therapeutics	$2.20B	0.71	-$713.41M	-$0.96	N/A

PTC Therapeutics has a beta of 0.56, suggesting that its stock price is 44% less volatile than the broader market. Comparatively, Sarepta Therapeutics has a beta of 0.24, suggesting that its stock price is 76% less volatile than the broader market.

PTC Therapeutics currently has a consensus price target of $95.75, indicating a potential upside of 40.79%. Sarepta Therapeutics has a consensus price target of $24.72, indicating a potential upside of 66.37%. Given Sarepta Therapeutics' higher probable upside, analysts clearly believe Sarepta Therapeutics is more favorable than PTC Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PTC Therapeutics	2 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.79
Sarepta Therapeutics	6 Sell rating(s)	6 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.14

Summary

PTC Therapeutics and Sarepta Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does Sarepta Therapeutics compare to Xenon Pharmaceuticals?

Xenon Pharmaceuticals (NASDAQ:XENE) and Sarepta Therapeutics (NASDAQ:SRPT) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, risk, analyst recommendations, profitability, media sentiment, dividends, earnings and valuation.

Xenon Pharmaceuticals has higher earnings, but lower revenue than Sarepta Therapeutics. Sarepta Therapeutics is trading at a lower price-to-earnings ratio than Xenon Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xenon Pharmaceuticals	$7.50M	807.77	-$345.91M	-$4.70	N/A
Sarepta Therapeutics	$2.20B	0.71	-$713.41M	-$0.96	N/A

Xenon Pharmaceuticals has a beta of 0.62, meaning that its share price is 38% less volatile than the broader market. Comparatively, Sarepta Therapeutics has a beta of 0.24, meaning that its share price is 76% less volatile than the broader market.

Xenon Pharmaceuticals has a net margin of 0.00% compared to Sarepta Therapeutics' net margin of -2.94%. Sarepta Therapeutics' return on equity of 7.56% beat Xenon Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Xenon Pharmaceuticals	N/A	-49.23%	-46.42%
Sarepta Therapeutics	-2.94%	7.56%	2.94%

Xenon Pharmaceuticals currently has a consensus price target of $77.20, indicating a potential upside of 23.18%. Sarepta Therapeutics has a consensus price target of $24.72, indicating a potential upside of 66.37%. Given Sarepta Therapeutics' higher possible upside, analysts clearly believe Sarepta Therapeutics is more favorable than Xenon Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xenon Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	2 Strong Buy rating(s)	3.00
Sarepta Therapeutics	6 Sell rating(s)	6 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.14

In the previous week, Xenon Pharmaceuticals had 6 more articles in the media than Sarepta Therapeutics. MarketBeat recorded 21 mentions for Xenon Pharmaceuticals and 15 mentions for Sarepta Therapeutics. Xenon Pharmaceuticals' average media sentiment score of 1.40 beat Sarepta Therapeutics' score of 0.76 indicating that Xenon Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Xenon Pharmaceuticals	16 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Sarepta Therapeutics	8 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

95.5% of Xenon Pharmaceuticals shares are owned by institutional investors. Comparatively, 86.7% of Sarepta Therapeutics shares are owned by institutional investors. 2.9% of Xenon Pharmaceuticals shares are owned by insiders. Comparatively, 6.9% of Sarepta Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Xenon Pharmaceuticals beats Sarepta Therapeutics on 11 of the 17 factors compared between the two stocks.

How does Sarepta Therapeutics compare to Centessa Pharmaceuticals?

Sarepta Therapeutics (NASDAQ:SRPT) and Centessa Pharmaceuticals (NASDAQ:CNTA) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, dividends, earnings, valuation, media sentiment, profitability and analyst recommendations.

Centessa Pharmaceuticals has a net margin of 0.00% compared to Sarepta Therapeutics' net margin of -2.94%. Sarepta Therapeutics' return on equity of 7.56% beat Centessa Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sarepta Therapeutics	-2.94%	7.56%	2.94%
Centessa Pharmaceuticals	N/A	-60.37%	-44.17%

86.7% of Sarepta Therapeutics shares are held by institutional investors. Comparatively, 82.0% of Centessa Pharmaceuticals shares are held by institutional investors. 6.9% of Sarepta Therapeutics shares are held by insiders. Comparatively, 4.1% of Centessa Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Sarepta Therapeutics has a beta of 0.24, indicating that its share price is 76% less volatile than the broader market. Comparatively, Centessa Pharmaceuticals has a beta of 1.11, indicating that its share price is 11% more volatile than the broader market.

Centessa Pharmaceuticals has lower revenue, but higher earnings than Sarepta Therapeutics. Centessa Pharmaceuticals is trading at a lower price-to-earnings ratio than Sarepta Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sarepta Therapeutics	$2.20B	0.71	-$713.41M	-$0.96	N/A
Centessa Pharmaceuticals	N/A	N/A	-$197.53M	-$1.79	N/A

In the previous week, Sarepta Therapeutics had 15 more articles in the media than Centessa Pharmaceuticals. MarketBeat recorded 15 mentions for Sarepta Therapeutics and 0 mentions for Centessa Pharmaceuticals. Sarepta Therapeutics' average media sentiment score of 0.76 beat Centessa Pharmaceuticals' score of 0.00 indicating that Sarepta Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Sarepta Therapeutics	Positive
Centessa Pharmaceuticals	Neutral

Sarepta Therapeutics presently has a consensus price target of $24.72, suggesting a potential upside of 66.37%. Centessa Pharmaceuticals has a consensus price target of $41.33, suggesting a potential upside of 2.06%. Given Sarepta Therapeutics' higher probable upside, research analysts clearly believe Sarepta Therapeutics is more favorable than Centessa Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sarepta Therapeutics	6 Sell rating(s)	6 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.14
Centessa Pharmaceuticals	1 Sell rating(s)	9 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.21

Summary

Sarepta Therapeutics beats Centessa Pharmaceuticals on 11 of the 15 factors compared between the two stocks.

Get Sarepta Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SRPT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SRPT vs. The Competition

Export

Metric	Sarepta Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.57B	$3.55B	$7.17B	$12.47B
Dividend Yield	N/A	3.79%	2.60%	10.03%
P/E Ratio	-15.48	4.31	222.53	22.11
Price / Sales	0.71	1,250.60	584.70	90.03
Price / Cash	N/A	44.80	28.60	46.71
Price / Book	1.36	16.78	10.93	6.07
Net Income	-$713.41M	-$12.56M	$3.50B	$348.34M
7 Day Performance	-5.23%	-1.47%	-0.24%	0.09%
1 Month Performance	-22.93%	-8.45%	-3.70%	-5.17%
1 Year Performance	-6.60%	48.32%	61.98%	18.61%

Sarepta Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SRPT Sarepta Therapeutics	3.5154 of 5 stars	$14.86 -4.5%	$24.72 +66.4%	-6.6%	$1.57B	$2.20B	N/A	1,372	Upcoming Earnings Analyst Forecast
CTMX CytomX Therapeutics	2.593 of 5 stars	$3.25 +0.3%	$12.10 +272.3%	+31.9%	$551.41M	$76.20M	N/A	170	News Coverage Positive News Upcoming Earnings
EDIT Editas Medicine	3.0015 of 5 stars	$2.68 +3.1%	$5.40 +101.5%	+5.7%	$254.56M	$40.52M	N/A	230	News Coverage Positive News
PTCT PTC Therapeutics	4.4085 of 5 stars	$75.80 -1.3%	$92.29 +21.7%	+30.5%	$6.37B	$1.73B	N/A	1,410	Trending News Earnings Report Analyst Forecast Short Interest Decrease
XENE Xenon Pharmaceuticals	3.1308 of 5 stars	$65.78 +0.6%	$77.20 +17.4%	+105.5%	$6.32B	$7.50M	N/A	210	News Coverage Positive News Analyst Upgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SRPT) was last updated on 8/2/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Sarepta Therapeutics (SRPT) Competitors

SRPT vs. CTMX, EDIT, PTCT, XENE, and CNTA

How does Sarepta Therapeutics compare to CytomX Therapeutics?

Summary

How does Sarepta Therapeutics compare to Editas Medicine?

Summary

How does Sarepta Therapeutics compare to PTC Therapeutics?

Summary

How does Sarepta Therapeutics compare to Xenon Pharmaceuticals?

Summary

How does Sarepta Therapeutics compare to Centessa Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SRPT vs. The Competition

Sarepta Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Sarepta Therapeutics (SRPT) Competitors

SRPT vs. CTMX, EDIT, PTCT, XENE, and CNTA

How does Sarepta Therapeutics compare to CytomX Therapeutics?

Does the media refer more to CTMX or SRPT?

Which has higher earnings and valuation, CTMX or SRPT?

Do institutionals & insiders have more ownership in CTMX or SRPT?

Is CTMX or SRPT more profitable?

Which has more volatility & risk, CTMX or SRPT?

Do analysts rate CTMX or SRPT?

Summary

How does Sarepta Therapeutics compare to Editas Medicine?

Which has preferable earnings and valuation, EDIT or SRPT?

Which has more volatility & risk, EDIT or SRPT?

Do analysts recommend EDIT or SRPT?

Is EDIT or SRPT more profitable?

Does the media favor EDIT or SRPT?

Do institutionals & insiders hold more shares of EDIT or SRPT?

Summary

How does Sarepta Therapeutics compare to PTC Therapeutics?

Is PTCT or SRPT more profitable?

Does the media refer more to PTCT or SRPT?

Do institutionals and insiders have more ownership in PTCT or SRPT?

Which has stronger earnings and valuation, PTCT or SRPT?

Which has more volatility and risk, PTCT or SRPT?

Do analysts recommend PTCT or SRPT?

Summary

How does Sarepta Therapeutics compare to Xenon Pharmaceuticals?

Which has better earnings & valuation, XENE or SRPT?

Which has more volatility and risk, XENE or SRPT?

Is XENE or SRPT more profitable?

Do analysts prefer XENE or SRPT?

Does the media favor XENE or SRPT?

Do institutionals & insiders believe in XENE or SRPT?

Summary

How does Sarepta Therapeutics compare to Centessa Pharmaceuticals?

Is SRPT or CNTA more profitable?

Do institutionals & insiders believe in SRPT or CNTA?

Which has more risk and volatility, SRPT or CNTA?

Which has better earnings and valuation, SRPT or CNTA?

Does the media prefer SRPT or CNTA?

Do analysts rate SRPT or CNTA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SRPT vs. The Competition

Sarepta Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools